Senti Biosciences SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Change in certifying accountant · Financial statements and exhibits
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedSenti Biosciences (SNTI) effects 1-for-33 reverse stock split effective November 18, 2026, trading split-adjusted from November 19
Entry into a material definitive agreement · Unregistered sales of equity securities · Financial statements and exhibits
AI summary, unreviewedSenti Biosciences Holdings Signs Up to $4.55 Million Equity Commitment With Celadon-Affiliated Investor, Priced at Nasdaq Minimum Price
Departure/appointment of directors or officers · Other events
AI summary, unreviewedSenti Biosciences Announces Director Edward Mathers' Resignation and Sets October 30, 2026 Record Date for CVR Distribution
Entry into a material definitive agreement · Termination of a material definitive agreement · Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Financial statements and exhibits
AI summary, unreviewedSenti Biosciences Holdings closes merger, divests Midco and Opco, and issues $2.5 million of stock amid going-concern warning
Submission of matters to a vote of security holders
Other events
Departure/appointment of directors or officers
Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits
Entry into a material definitive agreement · Delisting notice / failure to meet listing standard
Entry into a material definitive agreement · Creation of a direct financial obligation